VANCOUVER, BC / ACCESSWIRE / November 15, 2016 / CVR Medical Corp. (CVM.V) (“CVR Medical“) is pleased to announce that CVR Global, its joint venture partner, has named Dr. Douglas Weaver to its Board of Directors. A renowned cardiovascular specialist, Dr. Weaver’s involvement strengthens CVR’s executive leadership with extensive academic and clinical experience.

From 2008 to 2009, Dr. Weaver was President of the American College of Cardiology (“ACC”), a 52,000-cardiovascular care member medical society whose mission is to transform cardiovascular care and improve heart health. The ACC leads in the formation of health policy, standards and guidelines. Named one of “America’s Top Doctors” by Castle Connolly, Dr. Weaver currently serves as System Medical Director for Heart and Cardiovascular Services for the Henry Ford Health System in Michigan. Regarded as one of the foremost experts in his field, he has published over 300 scientific articles, received multiple grants from leading medical research institutions, and been appointed to lead a number of other executive and safety committees and task forces. CVR Global and CVR Medical look forward to having Dr. Weaver’s insight and enthusiastic support as they progress toward market launch of the “Carotid Stenotic Scan” device.

Speaking in regards to this position, Dr. Weaver states, “I am excited to work with CVR on a project that fills what I believe is a void in the diagnostic world of cardiovascular medicine. As a member of the Board, I hope to bring a useful medical background and patient-centric viewpoint that can assist in designing the necessary studies to prove the concept, as well as determining the best targets for application of this great technology.”

For additional information on the organization, leadership, and current news please visit the newly launched company website www.CVRMed.com

About CVR Medical

CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the “Joint Venture”). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.


This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to the Joint Venture. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management’s current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company’s control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.
THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.